ISRN Oncology · 2012 · 14 citations · 21 references
MedicineGynecologyOncologyGynecologic OncologySurgical OncologyTumor PathologyBorderline Ovarian TumorsCancer BiomarkersMalignant NeoplasmsOvarian CancerOvarian PathologyTumor MarkersDisease-free Survival AnalysisHistopathologic StagingOvarian Cancer BiomarkersOvarian Tumor BiomarkersOvarian Tumor StagingPrognostic Tumor MarkersSerous Borderline Ovarian TumorsSerum Tumor Markers
The aim of this paper was to evaluate the parameters of blood count and tumor markers in borderline ovarian tumors. We evaluated 21 patients who had confirmed histopathologic diagnosis of borderline ovarian tumor. We recorded age, parity, tumor type, stage of cancer, serum levels of tumor markers (CA-125, CA-15.3, CA-19.9, CEA, AFP), and the parameters of blood count, fasting glucose, disease-free survival and overall. The patients were divided into two groups, stage IA (n = 13) and stage IB-IIIC (n = 8). The unpaired t-test and Fisher's exact test were used, with P values of less than 0.05 being considered to indicate statistical significance. Levels of red blood cells, hematocrit, and hemoglobin were significantly higher in stage IA when compared with stage IB-IIIC (P < 0.05). The levels of tumor marker CEA had a tendency to be higher in the group stage IB-IIIC (0.08). Abnormal levels of CEA and CA-19.9 were found more frequently in stages IB-IIIC. Therefore, parameters of blood count, CEA, and CA-19.9 should be targeted for further research in identifying prognostic factors in borderline tumors.
21
Malignant and semimalignant tumors of the ovary
Hc. Taylor · Medical Entomology and Zoology · 1929 · 284 citations
Long-term follow-up of serous ovarian tumors of low malignant potential
Jonathan F. Leake, John L. Currie, Neil B. Rosenshein et al. · Gynecologic Oncology · 1992 · 153 citations